John L. Marshall, MD | Authors

The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care

September 22, 2020

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discusses the implications of precision medicine for cancer care, and the need to make that care more accessible for the global community at large.

Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?

December 15, 2017

A previously healthy 36-year-old man initially presented to his primary care physician with occasional bloody stools and dull right upper quadrant pain. Blood was sometimes mixed into his stools but was more often seen on the toilet paper after wiping.

The Growing Challenge of Young Adults With Colorectal Cancer

May 16, 2017

In this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.

Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer

April 15, 2017

Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient.

Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction

June 15, 2016

Here we discuss the evolution of standard therapy for rectal cancer patients and the use of preoperative CRT for the treatment of locally advanced disease. Treatment schemes that have attempted to broaden the horizons of standard therapy include the use of induction chemotherapy and “watch-and-wait” approaches.

Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer

January 16, 2016

Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.

Maintenance Therapy for Colorectal Cancer

April 15, 2014

We have yet to establish a standard practice for maintenance therapy in metastatic colorectal cancer. Of course, ideally we could find a biomarker of benefit for patients who should be managed this way, but thus far we have had no such luck.

An 80-Year-Old Man Presents With Abdominal Pain and Tarry Stools

November 09, 2012

In this Stump the Professor video, two fellows test Dr. Marshall's diagnostic skills with a unique case study involving an 80-year-old patient who presents with abdominal pain, bilateral edema, weight loss, and dark, tarry stools.

Improving Harmonious Precision

October 23, 2012

During the past decade, targeted therapeutics have changed the landscape of cancer therapy with bold brush strokes, but the resulting images are still unclear. As we enter into the second decade of targeted therapy, our increased understanding of tumor biology together with cancer genomic sequencing tools will clearly show the way forward. It is imperative that we use these fine brushes, not only to improve precision, but in the end to realize the art of medicine.